Puma Biotechnology | PBYI - Assets


Puma Biotechnology reported $202.86M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Esperion Therapeutics USD 465.89M 101.87M Dec/2025
Exelixis USD 2.84B 20.87M Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Glaxosmithkline GBP 82.34B 102.25M Dec/2025
Incyte USD 7.34B 381.14M Mar/2026
MacroGenics USD 256.85M 13.92M Dec/2025
Moderna USD 11.49B 850M Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 207.62B 542M Mar/2026
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
Takeda JPY 15.41T 938.47B Dec/2025
TG Therapeutics USD 1.06B 38.23M Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026